使用白细胞表面生物标志物早期预测脓毒症:ExPRES-sepsis队列研究
该多中心队列研究在4个急诊科和ICU标准化流式细胞术检测47种白细胞生物标志物,比较疑似急性感染患者(队列1,n=272)与已确诊脓毒症ICU患者(队列2,n=59)及无感染/全身炎症但需住院的急诊患者(队列3,n=75)。脓毒症定义为急诊就诊后24小时和/或72小时序贯器官衰竭评估评分≥2。47种标志物中14种不可靠、17种无法区分三组;单变量分析仅中性粒细胞CD279升高(OR 1.78,95%CI 1.23-2.57;P=0.002)、单核细胞CD279升高(OR 1.32,95%CI 1.03-1.70;P=0.03)和单核细胞HLA-DR降低(OR 0.73,95%CI 0.55-0.97;P=0.03)与后续脓毒症相关。逻辑回归最优组合为中性粒细胞CD24升高、中性粒细胞CD279升高和单核细胞HLA-DR降低,但无组合具有临床相关预测效度。
要点
- 在急诊疑似急性感染患者中,中性粒细胞CD279升高与后续脓毒症相关(OR 1.78,95%CI 1.23-2.57;P=0.002)。
- 单核细胞CD279升高(OR 1.32,95%CI 1.03-1.70;P=0.03)和单核细胞HLA-DR降低(OR 0.73,95%CI 0.55-0.97;P=0.03)也与后续脓毒症相关。
- 逻辑回归最优组合为中性粒细胞CD24升高、中性粒细胞CD279升高和单核细胞HLA-DR降低,但无组合具有临床相关预测效度。
- 47种白细胞生物标志物中14种不可靠、17种无法区分三组,仅免疫抑制相关标志物与后续脓毒症相关。
适用人群与场景
- 急诊科就诊的疑似急性感染患者(队列1,n=272)
- ICU已确诊脓毒症患者(队列2,n=59)作为比较队列
- 急诊无感染或全身炎症但需住院的患者(队列3,n=75)作为比较队列
诊断标准与关键阈值
- 脓毒症定义:急诊就诊后24小时和/或72小时序贯器官衰竭评估评分≥2
研究设计与关键结果
- 多中心队列研究,在4个急诊科和ICU进行,2014年1月至2016年2月招募队列1、2、3分别为272、59、75例患者。
- 47种白细胞生物标志物中,14种不可靠,17种无法区分三个队列。
- 单变量分析:中性粒细胞CD279升高OR 1.78(95%CI 1.23-2.57;P=0.002)、单核细胞CD279升高OR 1.32(95%CI 1.03-1.70;P=0.03)、单核细胞HLA-DR降低OR 0.73(95%CI 0.55-0.97;P=0.03)与后续脓毒症相关。
- 逻辑回归最优组合为中性粒细胞CD24升高、中性粒细胞CD279升高和单核细胞HLA-DR降低,但无组合具有临床相关预测效度。
证据类型、等级与局限
- 证据类型:多中心队列研究
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,在急诊疑似急性感染患者中,免疫抑制生物标志物与后续脓毒症相关,但无生物标志物组合具有临床相关预测效度,尚不能用于床旁预测脓毒症。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Reliable biomarkers for predicting subsequent sepsis among patients with suspected acute infection are lacking. In patients presenting to emergency departments (EDs) with suspected acute infection, we aimed to evaluate the reliability and discriminant ability of 47 leukocyte biomarkers as predictors of sepsis (Sequential Organ Failure Assessment score ≥ 2 at 24 h and/or 72 h following ED presentation).
METHODS: In a multi-centre cohort study in four EDs and intensive care units (ICUs), we standardised flow-cytometric leukocyte biomarker measurement and compared patients with suspected acute infection (cohort-1) with two comparator cohorts: ICU patients with established sepsis (cohort-2), and ED patients without infection or systemic inflammation but requiring hospitalization (cohort-3).
RESULTS: Between January 2014 and February 2016, we recruited 272, 59 and 75 patients to cohorts 1, 2, and 3, respectively. Of 47 leukocyte biomarkers, 14 were non-reliable, and 17 did not discriminate between the three cohorts. Discriminant analyses for predicting sepsis within cohort-1 were undertaken for eight neutrophil (cluster of differentiation antigens (CD) CD15; CD24; CD35; CD64; CD312; CD11b; CD274; CD279), seven monocyte (CD35; CD64; CD312; CD11b; HLA-DR; CD274; CD279) and a CD8 T-lymphocyte biomarker (CD279). Individually, only higher neutrophil CD279 [OR 1.78 (95% CI 1.23-2.57); P = 0.002], higher monocyte CD279 [1.32 (1.03-1.70); P = 0.03], and lower monocyte HLA-DR [0.73 (0.55-0.97); P = 0.03] expression were associated with subsequent sepsis. With logistic regression the optimum biomarker combination was increased neutrophil CD24 and neutrophil CD279, and reduced monocyte HLA-DR expression, but no combination had clinically relevant predictive validity.
CONCLUSIONS: From a large panel of leukocyte biomarkers, immunosuppression biomarkers were associated with subsequent sepsis in ED patients with suspected acute infection.
CLINICAL TRIAL REGISTRATION: NCT02188992.
参考来源
- Shankar-Hari M, Datta D, Wilson J, et al. Early PREdiction of sepsis using leukocyte surface biomarkers: the ExPRES-sepsis cohort study. Intensive Care Med. 2018. PMID: 30291379. doi:10.1007/s00134-018-5389-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。